Generic Lidex Ointment by Lupin receives FDA approval
03 August 2017 | News
Lidex Ointment had US sales of USD 40.3 million
Source: Pixabay
Pharma company Lupin Limited has announced that United States Food and Drug Administration (USFDA) has finally approved its Fluocinonide Topical Ointment USP, 0.05% to market a generic version of County Line Pharmaceuticals, LLC’s Lidex Ointment, 0.05%.
Indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, Lupin’s Fluocinonide Topical Ointment USP, 0.05% is AB rated generic equivalent of LLC’s Lidex Ointment, 0.05%.
Lidex Ointment had US sales of USD 40.3 million (IMS MAT March 2017).
